In this context, administration of HPV16 E7 DNA vaccine adjuvanted with anti-PD-1 and secondary lymphoid-tissue chemokine (CCL21 or SLC) or the toll like receptor agonist and α-Galactosylceramide in tumor-bearing mice models resulted in both tumor regression and tumor growth suppression [16, 17]. The gene discussed is PDCD1; the disease is neoplasm.